(Q44395020)

2 December 2017

title

The effect of erythromycin on the pharmacokinetics of rosuvastatin (English)

1 reference

2 December 2017

1 reference

1 reference

K J Cooper

1

1 reference

2 December 2017

P D Martin

2

1 reference

2 December 2017

A L Dane

3

1 reference

2 December 2017

M J Warwick

4

1 reference

2 December 2017

A Raza

5

1 reference

2 December 2017

D W Schneck

6

1 reference

2 December 2017

publication date

1 April 2003

1 reference

European Journal of Clinical Pharmacology

2 December 2017

published in

1 reference

2 December 2017

volume

59

1 reference

2 December 2017

issue

1

1 reference

2 December 2017

page(s)

51-56

1 reference

Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Macrolide antibacterials. Drug interactions of clinical significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

No effect of age or gender on the pharmacokinetics of rosuvastatin: a new HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

The effect of fluconazole on the pharmacokinetics of rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistant cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Quantification of rosuvastatin in human plasma by automated solid-phase extraction using tandem mass spectrometric detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Erythromycin and the gut.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-003-0573-7

Erythromycin coadministration increases plasma atorvastatin concentrations

21 January 2018

1 reference

12 December 2020

In vitro metabolism of simvastatin in humans [SBT]identification of metabolizing enzymes and effect of the drug on hepatic P450s

1 reference

12 December 2020

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

12 December 2020

Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations

1 reference

12 December 2020

Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver

1 reference

12 December 2020

Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus

1 reference

12 December 2020

10.1007/S00228-003-0573-7

Identifiers

DOI

1 reference

2 December 2017

1 reference